Gene Therapy Market Research Report - Global Forecast till 2027

Global Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers, Others) – Forecast to 2027

ID: MRFR/HC/6927-HCR | February 2021 | Region: Global | 111 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Forecast

Global Gene Therapy Market was valued USD 524 million in2018 and expected to register a CAGR of 40.7%.

Market Synopsis

The research and development, along with increased investment in product development is driving the global gene therapy market.

Market Influencer

Acquisitions of small-scale companies by key players and a large number of ongoing clinical trials are driving the market.

Market Drivers

  • Robust product pipeline

  • Increasing investment by key players

  • High prevalence of target diseases and demand for innovative medication

Market Restraints

  • The high cost of product development

  • Stringent regulatory policies


By Product

  • Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018.

  • Luxturna: Luxturna is an Adeno Associated Virus (AAV) gene therapy for the treatment of retinal dystrophy.

  • Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.

  • Zolgensma: The brand Zolgensma has received provisional approval by the FDA for investigational product AVXS-101 (onasemnogene abeparvovec-xxxx).

  • Strimvelis: The drug is indicated for the treatment of severe combined immunodeficiency arising due to adenosine deaminase deficiency (ADA-SCID).

  • Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million.

  • Imlygic: It is the first oncolytic viral therapy

  • Others: This segment includes drugs which are ongoing pre-clinical or clinical trials.

By Indication

  • Oncology: The fastest-growing segment, due to the increasing prevalence of various types of cancer.

  • Genetic Diseases/ Disorders: The largest segment, due to the high number of approved products.

  • Others: Includes drugs, which are in Phase-3 of clinical trials, for indications like X-Linked Retinitis Pigmentosa, Hemophilia B, Leber Hereditary Optic Neuropathy, and Mucopolysaccharidosis Type IIIA amongst others.

By End-User

  • Hospitals & Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals.

  • Specialty Treatment Centers: A small segment, these centers provide treatments for specific diseases, for instance, cancer.

  • Others: This segment includes home care and senior citizen centers.

By Region

  • Americas: The largest regional market, due to the presence of key market players and high healthcare expenditure

  • Europe: The growth of this region is due to product launches by key players.

  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of people affected with diseases and rising awareness about gene therapy.

  • Middle East & Africa: The smallest market due to limited healthcare infrastructure.

Key Players

  • Amgen, Inc. (US)

  • Novartis AG (Switzerland)

  • Spark Therapeutics, Inc. (US)

  • Gilead Sciences, Inc. (US)

  • uniQure N.V. (Netherlands)

  • Orchard Therapeutics plc (UK)

  • Celgene Corporation (US)

  • Bristol-Myers Squibb Company (US)

  • Thermo Fisher Scientific Inc. (US)

  • CEVEC (Germany)

  • Lonza (Switzerland)

Frequently Asked Questions (FAQ) :

The global gene therapy market had reached a valuation of USD 524 MN in 2018.

The global gene therapy market is projected to grow at approximately 40.7% CAGR during forecast period (2019-2025).

Rising technological advances and favorable government initiatives.

North America holds the largest share in the global gene therapy market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.

This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.